GLP-1 Market
LLY $1166.51 ▼ -1.4% NVO $38.06 ▼ -1.3% PFE $28.37 ▼ -0.1% VKTX $26.65 ▼ -6.0% KLRA $10.77 ▼ -4.9% GPCR $22.31 ▼ -6.7% RHHBY $53.77 ▼ -0.6%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Canagliflozin

Company
Baylor Research Institute
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
12 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

12 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 14, 2026

Find a Clinical Trial Near Me

See recruiting studies for Canagliflozin and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT04662723

    Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

    Not yet reported Fondazione Schena 878 participants Est. completion 2028-12-31 2 sites
    Other conditions: Glomerulonephritis, Immunoglobulin A Nephropathy
    View official trial listing →
  • Recruiting NCT NCT05390892

    PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Not yet reported Brigham and Women's Hospital 6000 participants Est. completion 2029-03-01 36 sites
    Cardiovascular disease Other conditions: Type2Diabetes
    View official trial listing →
  • Recruiting NCT NCT05427084

    Canagliflozin Targeting Vascular Inflammation

    Not yet reported, Not yet reported Ottawa Heart Institute Research Corporation 24 participants Est. completion 2026-12 1 site
    Cardiovascular disease Other conditions: Diabetes Type 2
    View official trial listing →
  • Recruiting NCT NCT06182839

    Canagliflozin in Advanced Renal Disease With MRI Endpoints

    Not yet reported McGill University Health Centre/Research Institute of the McGill University Health Centre 92 participants Est. completion 2029-03-30 1 site
    Chronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT06291155

    Mechanism of SGLT2 Inhibition in the Kidney

    Not yet reported University of Michigan 20 participants Est. completion 2028-02-28 1 site
    Type 2 diabetesChronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT06528405

    The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

    Not yet reported National Taiwan University Hospital 264 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Acute Kidney Injury
    View official trial listing →
  • Recruiting NCT NCT06913647

    Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis

    Not yet reported McGill University Health Centre/Research Institute of the McGill University Health Centre 30 participants Est. completion 2028-12-31 1 site
    Chronic kidney disease Other conditions: ESRD
    View official trial listing →
  • Recruiting NCT NCT07076823

    Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer

    Not yet reported West China Hospital 15 participants Est. completion 2026-06-30 1 site Stand-alone
    Other conditions: Colorectal Cancer, SGLT-2 Inhibitor
    View official trial listing →
  • Recruiting NCT NCT07157475

    Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors

    Wroclaw Medical University 300 participants Est. completion 2026-12-31 1 site
    Other conditions: Peripheral Arterial Disease(PAD)
    View official trial listing →
  • Recruiting NCT NCT07309094

    Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

    Cardenal Herrera University 250 participants Est. completion 2028-12-31 1 site
    Chronic kidney diseaseType 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT07703163

    Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer

    Not yet reported West China Hospital 15 participants Est. completion 2028-07-31 1 site Stand-alone
    Other conditions: Solid Tumor, SGLT 2 Inhibitors
    View official trial listing →
  • Recruiting NCT NCT07711171

    Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment

    Not yet reported Fudan University 60 participants Est. completion 2026-10-30 1 site
    Type 2 diabetes Other conditions: Cognitive Impairment
    View official trial listing →
  • Completed NCT NCT00642278

    An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 451 participants Est. completion 2009-01 78 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
    View official trial listing →
  • Completed NCT NCT00650806

    A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 376 participants Est. completion 2008-09 36 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00963768

    A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 116 participants Est. completion 2007-12 3 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00968812

    CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

    Not yet reported Janssen Research & Development, LLC 1452 participants Est. completion 2013-01 138 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01022112

    An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes

    Not yet reported Tanabe Pharma Corporation 383 participants Est. completion 2010-09 6 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01032629

    CANVAS - CANagliflozin cardioVascular Assessment Study

    Not yet reported Janssen Research & Development, LLC 4330 participants Est. completion 2017-02-22 305 sites Stand-alone
    Type 2 diabetesCardiovascular disease Other conditions: Risk Factors
    View official trial listing →
  • Completed NCT NCT01064414

    An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

    Not yet reported Janssen Research & Development, LLC 272 participants Est. completion 2012-08 106 sites Stand-alone
    Type 2 diabetes Other conditions: Renal Insufficiency
    View official trial listing →
  • Completed NCT NCT01081834

    The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

    Not yet reported Janssen Research & Development, LLC 678 participants Est. completion 2012-03 78 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01106625

    The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)

    Not yet reported Janssen Research & Development, LLC 469 participants Est. completion 2012-04 76 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01106651

    A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

    Not yet reported Janssen Research & Development, LLC 716 participants Est. completion 2013-05 86 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01106677

    The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

    Not yet reported Janssen Research & Development, LLC 1284 participants Est. completion 2012-05 125 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01106690

    The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

    Not yet reported Janssen Research & Development, LLC 344 participants Est. completion 2012-07 83 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01128985

    A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 39 participants Est. completion 2010-07 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01137812

    The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

    Not yet reported Janssen Research & Development, LLC 756 participants Est. completion 2012-03 184 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01157000

    A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 9 participants Est. completion 2010-06 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01173549

    A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 26 participants Est. completion 2011-09 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01177150

    A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 71 participants Est. completion 2007-04
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01177163

    A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 29 participants Est. completion 2009-03 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01186588

    A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 24 participants Est. completion 2011-04 2 sites Stand-alone
    Other conditions: Healthy, Hepatic Insufficiency
    View official trial listing →
  • Completed NCT NCT01195324

    A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 14 participants Est. completion 2010-12 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01273558

    A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 28 participants Est. completion 2011-07 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01273571

    A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 18 participants Est. completion 2011-02 Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01281579

    A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 27 participants Est. completion 2011-04 Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01286103

    A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 34 participants Est. completion 2011-05 Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01294631

    A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 30 participants Est. completion 2011-07 Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01340664

    An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

    Not yet reported Janssen Research & Development, LLC 279 participants Est. completion 2012-04 61 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01340677

    A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 24 participants Est. completion 2011-08 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01343290

    The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 24 participants Est. completion 2011-06 Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01381887

    A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 37 participants Est. completion 2011-11 5 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01381900

    A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

    Not yet reported Janssen Research & Development, LLC 678 participants Est. completion 2012-11 25 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01387737

    Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

    Not yet reported Tanabe Pharma Corporation 1299 participants Est. completion 2012-12 7 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01395927

    A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 14 participants Est. completion 2011-08 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01413204

    Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

    Not yet reported Tanabe Pharma Corporation 272 participants Est. completion 2012-08 5 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01428284

    A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 14 participants Est. completion 2011-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01454622

    A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 64 participants Est. completion 2011-11 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01459094

    Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers

    Not yet reported Janssen Research & Development, LLC 24 participants Est. completion 2011-12
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01463228

    A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

    Not yet reported Janssen Research & Development, LLC 83 participants Est. completion 2012-01 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01463774

    A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

    Not yet reported Janssen Research & Development, LLC 74 participants Est. completion 2011-12 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01483781

    A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus

    Not yet reported Janssen Research & Development, LLC 36 participants Est. completion 2012-08 1 site Stand-alone
    Type 2 diabetes Other conditions: Plasma Volume
    View official trial listing →
  • Completed NCT NCT01508182

    A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers

    Not yet reported Janssen Research & Development, LLC 64 participants Est. completion 2012-03 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01508195

    A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers

    Not yet reported Janssen Research & Development, LLC 64 participants Est. completion 2012-03 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01512849

    A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

    Not yet reported Tanabe Pharma Corporation 24 participants Est. completion 2012-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01518712

    A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 64 participants Est. completion 2011-11 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01665638

    Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers

    Not yet reported Janssen-Cilag International NV 10 participants Est. completion 2012-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01707316

    A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers

    Not yet reported Janssen Research & Development, LLC 15 participants Est. completion 2012-08 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01714193

    A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 30 participants Est. completion 2008-03 Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01714206

    A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 18 participants Est. completion 2009-09 Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01718652

    A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 18 participants Est. completion 2011-04 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01733108

    A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 29 participants Est. completion 2008-09 Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01748526

    A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 16 participants Est. completion 2008-09 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01756404

    Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 80 participants Est. completion 2007-12-05 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01756417

    A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 18 participants Est. completion 2007-11 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01759576

    A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 40 participants Est. completion 2008-11 3 sites Stand-alone
    Other conditions: Renal Insufficiency, Healthy
    View official trial listing →
  • Completed NCT NCT01787357

    A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 60 participants Est. completion 2008-09 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01791231

    A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 6 participants Est. completion 2007-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01809327

    A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

    Not yet reported Janssen Research & Development, LLC 1186 participants Est. completion 2014-12-02 129 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01821027

    A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy Volunteers

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 22 participants Est. completion 2008-09 Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01877889

    A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers

    Not yet reported Janssen-Cilag International NV 60 participants Est. completion 2014-03 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01916863

    Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

    Not yet reported Lexicon Pharmaceuticals 25 participants 1 site Stand-alone
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT01939496

    Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

    Not yet reported Janssen Scientific Affairs, LLC 171 participants Est. completion 2015-04 57 sites Stand-alone
    Type 2 diabetes Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT01989754

    A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

    Not yet reported Janssen Research & Development, LLC 5813 participants Est. completion 2017-02-23 341 sites Stand-alone
    Type 2 diabetes Other conditions: Albuminuria
    View official trial listing →
  • Completed NCT NCT02000700

    A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

    Not yet reported Janssen Research & Development, LLC 17 participants Est. completion 2016-04 17 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02009488

    Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

    Not yet reported Janssen Research & Development, LLC 59 participants Est. completion 2017-01-03 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02025907

    A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

    Not yet reported Janssen Research & Development, LLC 218 participants Est. completion 2015-09 57 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02039245

    Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination

    Not yet reported Janssen Research & Development, LLC 12 participants Est. completion 2014-03 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02039258

    Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food

    Not yet reported Janssen Research & Development, LLC 24 participants Est. completion 2014-03 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02041234

    Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

    Not yet reported Khoo Teck Puat Hospital 40 participants Est. completion 2022-06 1 site
    Other conditions: Type II Diabetes in Subjects BMI 27 to 32
    View official trial listing →
  • Terminated NCT NCT02053116

    A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

    Not yet reported Pfizer 8 participants Est. completion 2014-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02065752

    A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

    Not yet reported Janssen Research & Development, LLC 2 participants Est. completion 2014-04 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02065791

    Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

    Not yet reported Janssen Research & Development, LLC 4401 participants Est. completion 2018-10-30 575 sites Stand-alone
    Type 2 diabetesChronic kidney disease
    View official trial listing →
  • Completed NCT NCT02071368

    A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

    Not yet reported Janssen Research & Development, LLC 3 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02073227

    A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

    Not yet reported Janssen Research & Development, LLC 52 participants Est. completion 2014-06 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02077803

    A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

    Not yet reported Janssen Research & Development, LLC 47 participants Est. completion 2014-07 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02139943

    A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

    Not yet reported Janssen Research & Development, LLC 352 participants Est. completion 2015-06 53 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Status unknown NCT NCT02142309

    Glycemic Durability After Metformin Failure

    Not yet reported University of Campania Luigi Vanvitelli 450 participants Est. completion 2017-01 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02220218

    Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

    Not yet reported Janssen Research & Development, LLC 2 participants Est. completion 2014-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02220907

    Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

    Not yet reported Tanabe Pharma Corporation 153 participants Est. completion 2016-02 6 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02220920

    Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

    Not yet reported Tanabe Pharma Corporation 146 participants Est. completion 2015-07 7 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02221180

    Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

    Not yet reported Janssen Research & Development, LLC 2 participants Est. completion 2014-11 1 site Stand-alone
    Other conditions: Bioequivalence
    View official trial listing →
  • Completed NCT NCT02227849

    Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus

    Not yet reported Tanabe Pharma Corporation 71 participants Est. completion 2016-03 4 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02243202

    Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

    Not yet reported Janssen Research & Development, LLC 335 participants Est. completion 2015-06 17 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Status unknown NCT NCT02284269

    Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus

    Pharmaceuticals and Medical Devices Agency, Japan 18000 participants
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02324842

    Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

    Not yet reported The University of Texas Health Science Center at San Antonio 45 participants Est. completion 2019-03-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02354222

    Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

    Not yet reported Tanabe Pharma Corporation 154 participants Est. completion 2016-02 3 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02354235

    Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

    Not yet reported Tanabe Pharma Corporation 138 participants Est. completion 2016-01 3 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02360774

    Mechanisms of Weight Loss With SGLT2 Inhibition

    Not yet reported Beth Israel Deaconess Medical Center 30 participants Est. completion 2018-08 1 site Stand-alone
    Type 2 diabetes Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT02404870

    Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 67 participants Est. completion 2019-09-03 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Terminated NCT NCT02462421

    Pharmacogenetics of SGLT2 Inhibitors

    Not yet reported University of Maryland, Baltimore 30 participants Est. completion 2021-12-31 Stand-alone
    Other conditions: Diabetes Mellitus, Gout, Hyperuricemia
    View official trial listing →
  • Status unknown NCT NCT02528019

    Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

    Not yet reported Kurume University 100 participants Est. completion 2018-08 1 site
    Other conditions: Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
    View official trial listing →
  • Completed NCT NCT02597049

    A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 424 participants Est. completion 2017-02 41 sites
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT02597309

    The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin

    Not yet reported Joslin Diabetes Center Est. completion 2017-07 1 site
    Other conditions: Diabetes, Obesity
    View official trial listing →
  • Completed NCT NCT02622113

    Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

    Not yet reported Tanabe Pharma Corporation 139 participants Est. completion 2016-04 7 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02624908

    Canagliflozin-Mealtime Insulin Rescue

    Not yet reported Foundation for Atlanta Veterans Education and Research, Inc. 40 participants Est. completion 2022-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02636192

    Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents

    Janssen Research & Development, LLC 200000 participants Est. completion 2017-04-07
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02653209

    TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.

    Not yet reported Royal Devon and Exeter NHS Foundation Trust 525 participants Est. completion 2021-01 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02673138

    Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

    Not yet reported Yale University 10 participants Est. completion 2017-07 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT02681497

    Use of Canagliflozin in Conjunction With Insulin in a Real-world Setting

    London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 269 participants Est. completion 2016-07 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02688075

    An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada

    Janssen Inc. 538 participants Est. completion 2017-08-17 23 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02694263

    Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan

    Not yet reported University of Leicester 25 participants Est. completion 2018-09-13 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02737657

    An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan

    Janssen-Cilag International NV 379 participants Est. completion 2016-09 9 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02846506

    A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

    Not yet reported Janssen Research & Development, LLC 44 participants Est. completion 2016-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02851095

    A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

    Not yet reported Janssen Research & Development, LLC 44 participants Est. completion 2016-11 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02851212

    A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

    Not yet reported Janssen Research & Development, LLC 44 participants Est. completion 2016-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02857764

    Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States

    Janssen Research & Development, LLC 127690 participants Est. completion 2017-06-30
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02865668

    A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

    Not yet reported Janssen Research & Development, LLC 44 participants Est. completion 2016-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT02891954

    Genetics of Response to Canagliflozin

    Not yet reported University of Maryland, Baltimore 700 participants Est. completion 2026-12-25 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT02912455

    CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

    Not yet reported The Cleveland Clinic 16 participants Est. completion 2018-07-19 1 site
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT02920918

    Treatment of Diabetes in Patients With Systolic Heart Failure

    Not yet reported Virginia Commonwealth University 36 participants Est. completion 2018-09 1 site
    Heart failureType 2 diabetes
    View official trial listing →
  • Completed NCT NCT02964585

    Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

    Not yet reported George Washington University 34 participants Est. completion 2020-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03136484

    Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

    Not yet reported Novo Nordisk A/S 788 participants Est. completion 2018-11-16 119 sites Added to GLP-1
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT03170518

    A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

    Not yet reported Janssen Research & Development, LLC 171 participants Est. completion 2023-09-20 106 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT03190798

    Effects of Canagliflozin on Intravascular Volume and Hemodynamics

    Not yet reported The University of Texas Health Science Center at San Antonio Est. completion 2018-08-01 1 site
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Completed NCT NCT03249506

    Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

    Janssen Research & Development, LLC 25358 participants Est. completion 2017-11-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03267576

    An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin

    Not yet reported Janssen Research & Development, LLC 64 participants Est. completion 2018-10-01 5 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT03298009

    Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)

    Not yet reported Université de Sherbrooke Est. completion 2018-06-30 Stand-alone
    Type 2 diabetesHeart failure
    View official trial listing →
  • Completed NCT NCT03422263

    Performance Under SGLT-2-Inhibitors in Humans

    Berner Klinik Montana 450 participants Est. completion 2020-09-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03426956

    Glucose Absorption and Gut Hormone Secretion After Gastric Bypass

    Not yet reported Hvidovre University Hospital 10 participants Est. completion 2019-05-01 1 site Stand-alone
    Other conditions: Overweight
    View official trial listing →
  • Completed NCT NCT03436693

    Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

    Not yet reported Tanabe Pharma Corporation 308 participants Est. completion 2021-01-21 26 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT03492580

    A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

    Janssen Research & Development, LLC 714582 participants Est. completion 2018-06-25 1 site
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Completed NCT NCT03604224

    A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting

    Johnson & Johnson Private Limited 178 participants Est. completion 2019-07-01 3 sites
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03627039

    Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

    Brigham and Women's Hospital 20000 participants Est. completion 2020-08-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03917758

    Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors

    Not yet reported University of Turin, Italy 30 participants Est. completion 2020-10-30 1 site
    Type 2 diabetes Other conditions: Arterial Hypertension, Body Weight Changes
    View official trial listing →
  • Completed NCT NCT03918148

    Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)

    University of Campania Luigi Vanvitelli 1150 participants Est. completion 2023-12-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03936010

    Replication of the CANVAS Diabetes Trial in Healthcare Claims

    Brigham and Women's Hospital 152202 participants Est. completion 2021-02-18 1 site
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT03939624

    Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

    Canadian Network for Observational Drug Effect Studies, CNODES 419734 participants Est. completion 2019-10-01 1 site
    Type 2 diabetesCardiovascular diseaseHeart failure Other conditions: Cardiovascular Death, All-Cause Mortality
    View official trial listing →
  • Status unknown NCT NCT04014192

    Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

    Not yet reported Peking Union Medical College Hospital 40 participants Est. completion 2020-07-31 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04017221

    Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes

    Canadian Network for Observational Drug Effect Studies, CNODES 1249636 participants Est. completion 2019-12-01 1 site
    Type 2 diabetes Other conditions: Urosepsis, Diabetic Ketoacidosis, Lower Extremity Amputation
    View official trial listing →
  • Status unknown NCT NCT04027023

    Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

    Not yet reported Sciema UG 9 participants Est. completion 2021-05-31 2 sites
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT04073680

    A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

    Not yet reported, Not yet reported Petra Pharma 60 participants Est. completion 2021-12-30 Stand-alone
    Other conditions: Breast Cancer, Endometrial Cancer, Lung Cancer, Colo-rectal Cancer, Head and Neck Cancer
    View official trial listing →
  • Status unknown NCT NCT04127084

    Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes

    Not yet reported Zhongshan Hospital Xiamen University 70 participants Est. completion 2021-08 1 site Stand-alone
    Type 2 diabetesChronic kidney disease
    View official trial listing →
  • Completed NCT NCT04184947

    Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

    University of Padova 10000 participants Est. completion 2020-02-29 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04196231

    Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

    Not yet reported University of Campania Luigi Vanvitelli 258 participants Est. completion 2020-10-20 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04252287

    A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure

    Not yet reported Janssen Research & Development, LLC 476 participants Est. completion 2021-11-09 18 sites Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT04288778

    A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes

    Not yet reported Johnson & Johnson Private Limited 276 participants Est. completion 2022-07-26 10 sites Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT04304261

    Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)

    Not yet reported Third Military Medical University 100 participants Est. completion 2024-04-30 1 site Stand-alone
    Type 2 diabetes Other conditions: Cognitive Functions Confusion
    View official trial listing →
  • Status unknown NCT NCT04419337

    Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke

    Not yet reported Chang Gung Memorial Hospital 200 participants Est. completion 2024-01-31 1 site Stand-alone
    Cardiovascular disease Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT04505774

    Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

    Not yet reported Matthew Neal MD 3591 participants Est. completion 2024-01-26 101 sites
    Other conditions: Covid19
    View official trial listing →
  • Completed NCT NCT04700839

    SGLT2 Inhibitors in Patients With PCOS

    Not yet reported Shanghai 10th People's Hospital 68 participants Est. completion 2021-04-30 1 site
    Other conditions: Polycystic Ovary Syndrome
    View official trial listing →
  • Status unknown NCT NCT04720859

    Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)

    Not yet reported Hospital Universitari Vall d'Hebron Research Institute 40 participants Est. completion 2022-12-31 1 site Stand-alone
    Other conditions: Postprandial Hypoglycemia
    View official trial listing →
  • Status unknown NCT NCT04796428

    GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

    Not yet reported Center for Outcomes Research and Clinical Epidemiology, Italy 1167 participants Est. completion 2023-12-31
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04973891

    CANA/Met in Non-diabetic Women With PCOS

    Not yet reported, Not yet reported Shengjing Hospital 52 participants Est. completion 2022-03-08 1 site Stand-alone
    Other conditions: Polycystic Ovary Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT05090358

    Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 15 participants Est. completion 2027-10-08 9 sites Stand-alone
    Other conditions: Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05135039

    Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV.

    Not yet reported xiaolong zhao 218 participants Est. completion 2024-12-31 1 site Stand-alone
    Prediabetes Other conditions: Hiv
    View official trial listing →
  • Status unknown NCT NCT05161429

    BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

    Brigham and Women's Hospital 550000 participants Est. completion 2024-06-30 5 sites
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT05220917

    Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

    Brigham and Women's Hospital 781430 participants Est. completion 2027-09-30 1 site
    Type 2 diabetes Other conditions: Cardiovascular Events, Renal Disease
    View official trial listing →
  • Completed NCT NCT05309785

    Safety and Efficacy of Canagliflozin in Advanced CKD

    Not yet reported McGill University Health Centre/Research Institute of the McGill University Health Centre 34 participants Est. completion 2026-07-01 1 site
    Chronic kidney disease Other conditions: ESRD
    View official trial listing →
  • Status unknown NCT NCT05333159

    The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.

    Beijing Anzhen Hospital 1424 participants Est. completion 2024-12-30 1 site
    Cardiovascular disease Other conditions: Diabete Mellitus
    View official trial listing →
  • Status unknown NCT NCT05347459

    Cognitive Protective Effect of Newer Antidiabetic Drugs

    Alexandria University 100 participants Est. completion 2023-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05364190

    Canagliflozin in Patients With Acute Decompansted Heart Failure

    Not yet reported October 6 University 142 participants Est. completion 2024-03-01 1 site Stand-alone
    Heart failure Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT05367063

    Canagliflozin and Myocardial Fibrosis

    Not yet reported Shanghai Zhongshan Hospital 45 participants Est. completion 2025-03-20 1 site
    Type 2 diabetes Other conditions: Cardiovascular Risk
    View official trial listing →
  • Status unknown NCT NCT05422092

    Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

    Not yet reported First Affiliated Hospital Xi'an Jiaotong University 80 participants Est. completion 2023-12 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05477017

    Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients

    University of Milan 800 participants Est. completion 2023-03 1 site
    Other conditions: Type2Diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT05507892

    Renal Mechanism of SGLT2 Inhibition

    Not yet reported University of Colorado, Denver 45 participants Est. completion 2026-12-15 2 sites Stand-alone
    Type 2 diabetesChronic kidney disease
    View official trial listing →
  • Status unknown NCT NCT05513729

    Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

    First Affiliated Hospital Xi'an Jiaotong University 80 participants Est. completion 2024-03-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05612269

    SGLT2 Inhibitors and Reducing the Risk of Cancers Among Diabetics , an Observational Study

    Ministry of Health, Saudi Arabia 200 participants Est. completion 2024-01-31 1 site
    Type 2 diabetes Other conditions: Cancer, Interleukin 6, SGLT2 Inhibitors
    View official trial listing →
  • Completed NCT NCT05764811

    SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

    Not yet reported National Cheng-Kung University Hospital 40 participants Est. completion 2022-12-31 1 site
    Other conditions: Fatty Liver Disease
    View official trial listing →
  • Status unknown NCT NCT05856578

    Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 Diabetes

    Not yet reported Nanjing First Hospital, Nanjing Medical University 60 participants Est. completion 2023-12-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT05903703

    Canagliflozin With Gemcitabine in Pancreatic Carcinoma

    Not yet reported Zhang Xiaofeng,MD 20 participants Est. completion 2027-03-31 1 site Stand-alone
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT06099067

    Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

    AstraZeneca 239990 participants Est. completion 2023-08-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT06187493

    Treatment of Patients With Diabetic Kidney Disease

    Not yet reported Assiut University 70 participants Est. completion 2025-12-31
    Chronic kidney disease
    View official trial listing →
  • Status unknown NCT NCT06256289

    Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome

    Not yet reported Ping Li,MD 50 participants Est. completion 2025-04-30 Stand-alone
    Other conditions: Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
    View official trial listing →
  • Completed NCT NCT06301529

    The Efficacy and Tolerability of Canagliflozin in Healthy Individual

    Not yet reported AgelessRx 30 participants Est. completion 2024-06-29 1 site Stand-alone
    Other conditions: Healthy Aging
    View official trial listing →
  • Status unknown NCT NCT06449235

    Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

    Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders 938 participants Est. completion 2025-06 1 site
    Other conditions: Type2diabetes
    View official trial listing →
  • Completed NCT NCT06851962

    Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

    Not yet reported Fundación para la Investigación del Hospital Clínico de Valencia 92 participants Est. completion 2026-06-30 3 sites Added to GLP-1
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT06858436

    SGLT2 Inhibitor Utilization Re-perfusion Therapy

    Not yet reported Taichung Veterans General Hospital 150 participants Est. completion 2027-10-31 Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Active, not recruiting NCT NCT07188545

    Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

    Ohio State University 23280000 participants Est. completion 2029-06-30 1 site
    Metabolic syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT07325435

    Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

    Not yet reported MaryAnn Banerji 60 participants Est. completion 2028-06-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07391267

    Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.

    Not yet reported Institute of Liver and Biliary Sciences, India 90 participants Est. completion 2028-12-31 1 site Added to GLP-1
    Chronic kidney disease Other conditions: MAFLD
    View official trial listing →
  • Not yet recruiting NCT NCT07527390

    CANagliflozin In DIALysis Patients

    Not yet reported University Medical Center Groningen 10 participants Est. completion 2027-01-30 1 site Stand-alone
    Chronic kidney disease Other conditions: Dialysis
    View official trial listing →
  • Enrolling by invitation NCT NCT07547878

    Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

    Not yet reported Baylor Research Institute 64 participants Est. completion 2029-03-31 1 site
    Chronic kidney diseaseType 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Canagliflozin, INVOKANA

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.